Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer.

[1]  D. Carbone,et al.  Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. , 2021, Journal of geriatric oncology.

[2]  Page Widick,et al.  Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy , 2021, JAMA network open.

[3]  Manoj Kumar,et al.  Real-World Outcomes and Clinical Predictors of Immune Checkpoint Inhibitor Monotherapy in Advanced Lung Cancer , 2021, Clinical Medicine Insights. Oncology.

[4]  D. Carbone,et al.  Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. , 2020 .

[5]  A. Rossi,et al.  Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study. , 2020, Clinical lung cancer.

[6]  J. Milanowski,et al.  CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. , 2020, European journal of cancer.

[7]  I. Wilson,et al.  Real‐world use and survival outcomes of immune checkpoint inhibitors in older adults with non–small cell lung cancer , 2020, Cancer.

[8]  J. Uchino,et al.  Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer , 2019, Journal of Cancer Research and Clinical Oncology.

[9]  S. Dalle,et al.  Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting. , 2019, European journal of cancer.

[10]  K. Syrigos,et al.  Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. , 2019, The New England journal of medicine.

[11]  L. Einhorn,et al.  Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153). , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  H. Morgenstern,et al.  Body mass index (BMI), BMI change, and overall survival in small cell and non-small cell lung cancer patients: a pooled analysis of the International Lung Cancer Consortium. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Y. Hosomi,et al.  Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. , 2019, Lung cancer.

[14]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[15]  M. Strawderman,et al.  Immune Checkpoint Inhibitors in Real‐World Treatment of Older Adults with Non–Small Cell Lung Cancer , 2019, Journal of the American Geriatrics Society.

[16]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[17]  Toyoaki Hida,et al.  Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  P. Keegan,et al.  FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies. , 2018, Seminars in oncology.

[19]  C. Gridelli,et al.  Lung cancer, elderly and immune checkpoint inhibitors. , 2018, Journal of thoracic disease.

[20]  D. Mytelka,et al.  Post‐diagnosis weight loss as a prognostic factor in non‐small cell lung cancer , 2017, Journal of cachexia, sarcopenia and muscle.

[21]  N. Chaput,et al.  Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter? , 2017, Cancer treatment reviews.

[22]  A. Giobbie-Hurder,et al.  Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. , 2017, The oncologist.

[23]  C. Presley,et al.  Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults , 2017, Current Oncology Reports.

[24]  R. Bourgon,et al.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , 2017, The Lancet.

[25]  J. Sosman,et al.  Responses to immune checkpoint inhibitors in nonagenarians , 2016, Oncoimmunology.

[26]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[27]  Carlino,et al.  Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma , 2016 .

[28]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[29]  S. Moschos,et al.  Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. , 2016, Cancer treatment reviews.

[30]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[31]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[32]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[33]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[34]  C. Gridelli,et al.  Management of elderly patients with NSCLC; updated expert's opinion paper: EORTC Elderly Task Force, Lung Cancer Group and International Society for Geriatric Oncology. , 2014 .

[35]  Masahiko Ando,et al.  Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Labianca,et al.  Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  B. Milleron,et al.  Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  R. Gress,et al.  The aging immune system and its relationship with cancer. , 2011, Aging health.

[39]  G. Pawelec,et al.  Potential role of immunosenescence in cancer development , 2010, Annals of the New York Academy of Sciences.

[40]  K. Krejcy,et al.  Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study , 2009, The Lancet.

[41]  Taofeek K Owonikoko,et al.  Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Joy H. Lewis,et al.  Participation of patients 65 years of age or older in cancer clinical trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  R. Stephens,et al.  Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome , 2000, British Journal of Cancer.

[44]  M. Kris,et al.  Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens , 2000 .

[45]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[47]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.